Molecular Imaging

NNSA's Mo-99 program: A bumpy ride

Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).

October 10, 2024

FES-PET improves management of breast cancer patients

PET/CT imaging with F-18 fluroestradiol (FES) can play a significant role in helping clinicians make treatment decisions in patients with recurrent or metastatic breast cancer

October 7, 2024

2024 10 07 Fes Pet Thumbnail

What impact will flurpiridaz F-18 have on heart care?

Seventeen years was all it took for flurpiridaz F-18 to reach the market, with the first patient injected with the PET imaging agent in November, 2007.

October 4, 2024

PET identifies risk of metastases in patients with HNSCC

PET imaging with F-18 fluoromisonidazole can determine whether cancer may spread in patients undergoing chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).

October 1, 2024

Nuclear cardiology could face cuts in 2025

Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert.

September 25, 2024

Larry Phillips, MD

How effective is Pluvicto in a ‘real-world’ setting?

Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.

September 20, 2024

Microplastics reach the olfactory bulb in the human brain

Pathologists have detected microplastics in olfactory bulb brain tissues of eight deceased individuals in Sao Paulo, Brazil.

September 19, 2024

Olfactory Bulb Brain

NYC researchers propose criteria for FMISO-PET imaging

Proposed criteria for F-18 fluoromisonidazole (FMISO) PET imaging can help clinicians manage patients with head and neck cancer.

September 17, 2024

A graphical abstract of the study. Image courtesy of the Journal of Nuclear Medicine.

Radiotracer for kidney cancer performs well in phase III trial

A PET radiotracer that detects clear-cell renal cell carcinoma proved safe and highly effective in a clinical trial conducted at 36 research hospitals across nine countries.

September 12, 2024

Pet Renal Cancer 66e1e00428375 Thumbnail

Cardiac PET use increases in coronary artery disease

PET, CT, and MRI use for assessing coronary artery disease increased in Medicare patients from 2018 to 2022.

September 11, 2024

AI may help visualize cardiac sarcoidosis

A deep-learning AI model shows promise in helping clinicians assess cardiac sarcoidosis on PET scans.

September 9, 2024

Examples of the standard myocardial perfusion imaging (MPI) segmentation, DL segmentation, and manual segmentation for negative (a) and positive (b) FDG-PET studies. Image courtesy of the American Society of Nuclear Cardiology.

PET tracer reveals treatment responses in cardiac amyloidosis patients

PET/CT imaging with iodine-124 evuzamitide may help monitor how patients with cardiac amyloidosis respond to therapy over time.

September 6, 2024

I-124 evuzamitide PET/CT images of a patient with light-chain amyloidosis showing a decrease in amyloid load and organ volume on follow-up.

Page 1 of 597